Allarity Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Allarity Therapeutics, Inc. Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage precision medicine biotechnology company that develops novel oncology therapeutics and proprietary Drug Response Predictor (DRP®) companion diagnostics for personalized treatment of patients with difficult-to-treat cancers, including advanced recurrent ovarian cancer; its lead product candidate is stenoparib, an orally available small molecule dual inhibitor of PARP1/2 and Tankyrase enzymes that demonstrates clinical benefit in DRP®-selected patients and shows potential to overcome resistance to other PARP inhibitors while supporting combination therapies due to low myelotoxicity; the company also advances stenoparib-DRP® companion diagnostics and supports select external programs involving DRP® applications across tumor types such as breast cancer and multiple myeloma. Founded in 2004 as Medical Prognosis Institute A/S in Denmark and reorganized in 2021 into a U.S. corporation headquartered in Boston, Massachusetts, with an R&D facility in Hørsholm, Denmark, Allarity Therapeutics, Inc. operates globally with exclusive worldwide rights to stenoparib, partnered GMP manufacturing with Lonza, and targets unmet needs in oncology through patient stratification to enhance clinical success rates. Recent developments include the initiation of enrollment in a Phase 2 trial of stenoparib in advanced ovarian cancer in 2025, expansion of intellectual property with Australian patent acceptance for stenoparib-DRP®, a new non-exclusive global licensing agreement for breast cancer DRP® with an EU-based biotech partner including laboratory services revenue, development and presentation of a daratumumab-specific DRP® for multiple myeloma at AACR 2025, and the appointment of Jesper Høiland to the board in June 2025 to bolster commercialization strategy.
Company News
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm